Woman drinking smoothie with liquid B-Complex for preconception

Why the Preconception Formula You've Been Describing in Every MTHFR Community Finally Exists in Liquid Form

June 25, 2026 34 MINS READ
Share:
BLOG / Health & Wellness Library / Why the Preconception Formula You've Been Describing in Every MTHFR Community Finally Exists in Liquid Form

Your OB/GYN said take folate. Your functional medicine naturopath said the folate in your prenatal is the wrong form. Your genetic panel confirmed your MTHFR C677T variant reduces the activity of the enzyme that converts folic acid to its active form. You've spent three weeks researching. You've confirmed that you need L-5-MTHF, but at a higher dose than the compliance dose on most premium capsule labels. If you're searching for the best B-complex for preconception with MTHFR, the gap you keep hitting is real, and it's specific.

You need the 40:1 inositol ratio your naturopath mentioned. You need tri-form B12, not just methylcobalamin. And you need it in liquid, because you're already managing six separate products every morning and the compliance math doesn't work during a window where the consistency of active-form nutritional support matters most.

For MTHFR-variant women in preconception preparation, the difference between folic acid and active-form folate is a specific, pharmacokinetically documented reality, and the market has consistently offered partial solutions while calling them complete.

BioActive B-Complex™ is a liquid B-vitamin system formulated with clinically-studied ingredients for MTHFR-variant women in preconception preparation who want active-form L-5-MTHF at a meaningful dose, tri-form B12 coverage, and the physiological 40:1 inositol ratio, without relying on the enzymatic conversion step that standard prenatal B-vitamins depend on.*

The formula you've been describing in every practitioner appointment and every online community exists: in liquid, in amber glass, in one daily teaspoon.

 

 


What Is the Best B-Complex for Preconception With MTHFR?


For women with MTHFR variants preparing for conception, BioActive B-Complex™ is a liquid B-vitamin system combining active-form L-5-MTHF at a meaningful dose, tri-form B12 coverage, and the physiological 40:1 myo-inositol/D-chiro-inositol ratio. These are three of the nutritional priorities functional medicine practitioners most consistently discuss for MTHFR-variant preconception preparation.

The complete active-form B-vitamin architecture delivers folate in its finished, pre-converted form, so it does not depend on the MTHFR enzyme step that variant carriers have reduced activity in. It delivers L-5-MTHF at 3,400 mcg DFE in a form the body can use directly, regardless of MTHFR genotype status.

Unlike standard prenatals and even premium capsule B-complexes that use folic acid or lower-dose methylfolate, BioActive B-Complex™ delivers a complete preconception B-vitamin foundation: active folate at a meaningful dose, benfotiamine (a fat-soluble form of B1), all three cobalamin forms, and the studied inositol ratio, all in liquid form that mixes directly into a morning smoothie.*

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

 

 


How Complete Active-Form B-Vitamin Architecture Supports Healthy Preconception Methylation for MTHFR-Variant Women, Without Relying on Folic Acid Conversion


L-5-MTHF at 3,400 mcg DFE. Tri-form B12. Physiological 40:1 myo-inositol/D-chiro-inositol ratio. Benfotiamine. One liquid teaspoon designed for how your MTHFR variant actually works.

BioActive B-Complex™ is a clinical-grade liquid B-vitamin system developed by Triquetra Health specifically for MTHFR-variant women in preconception preparation who want active-form B-vitamin delivery that does not depend on the enzymatic conversion step affected by common MTHFR variants.

The formulation delivers the B-vitamins in pre-activated coenzyme forms, combining L-5-MTHF calcium salt at 3,400 mcg DFE with benfotiamine (a fat-soluble form of B1 with documented bioavailability advantages over thiamine HCl), a tri-form B12 complex covering methylcobalamin, adenosylcobalamin, and hydroxocobalamin, pyridoxal-5'-phosphate (P-5-P) as the direct active B6 coenzyme, pantethine as a B5 form studied in a dedicated cardiovascular outcomes RCT, and the physiological 40:1 myo-inositol/D-chiro-inositol ratio studied in a meta-analysis of 9 clinical trials in women with PCOS (Unfer et al., 2017).

BioActive B-Complex™ is a liquid B-complex combining this complete active-form architecture in a preconception-appropriate liquid B-vitamin system. It supports healthy folate metabolism regardless of MTHFR genotype, supports healthy homocysteine levels already within normal range, and supports insulin signal transduction and healthy hormonal parameters through a complete daily teaspoon in organic vegetable glycerin base, packaged in amber glass for ingredient photostability.*

BioActive B-Complex™ uses a complete active-form B-vitamin architecture to deliver L-5-MTHF, benfotiamine, and tri-form B12 in forms that support cellular methylation pathways directly, unlike standard prenatal B-complexes that rely on the folic acid conversion step that common MTHFR variants reduce.*

See the complete preconception protocol ↓

 

 


Is Liquid B-Complex Better Than Capsules for Preconception?


For preconception B-vitamin supplementation, liquid delivery offers meaningful practical advantages over capsules during a period when daily compliance is important and supplement stack complexity is already high. Liquid B-vitamins do not require the dissolution and disintegration steps that tablets and capsules go through before absorption can begin, delivering ingredients in solution.

BioActive B-Complex™  is formulated in an organic vegetable glycerin base that supports the fat-soluble absorption of benfotiamine. The amber glass packaging helps protect photosensitive ingredients such as riboflavin and pyridoxal-5'-phosphate from light degradation, helping ensure the formula shipped is the formula received.

For women managing complex preconception supplement protocols (often including methylfolate, separate B12, fish oil, CoQ10, and magnesium), one teaspoon replacing three to four separate capsule products can reduce daily compliance burden during a window where consistency matters.

BioActive B-Complex™ is a liquid B-complex delivering active-form L-5-MTHF at a meaningful dose, tri-form B12, benfotiamine, and the physiological 40:1 myo-inositol/D-chiro-inositol ratio together in one liquid product, helping serve preconception nutritional priorities for MTHFR-variant women without requiring as many separate supplements.*

 

B-Complex for preconception

 

 

 


The Research Has Identified Exactly What You Need, and the Market Has Been Offering Partial Solutions


The Preconception Planner has done work that most supplement consumers never approach. You've identified your specific variant. You've learned that the reduced activity of the MTHFR enzyme in variant carriers means folic acid is converted to active folate less efficiently, so the folate labeled on your current prenatal may not all reach your methylation cycle in usable form. You've researched the 40:1 inositol ratio, the difference between methylcobalamin and adenosylcobalamin, and the clinical evidence for active folate at a meaningful dose.

Then you've opened every premium liquid product and found the same partial solution: standard folate instead of L-5-MTHF, methylcobalamin without adenosylcobalamin, no inositol ratio, compliance-level B-vitamin doses that were never calibrated for MTHFR-variant methylation demand.

The three gaps you've encountered aren't random. They're symptoms of a market that formulated B-complexes for general population averages, not for the complete active-form B-vitamin architecture that MTHFR-variant women specifically look for.

The active-form B-vitamin system in BioActive B-Complex™ was built from the pharmacokinetic evidence forward, starting from active-folate research and the inositol-ratio literature and working backward to every ingredient decision.

 

 


Why Standard Prenatal Vitamins, Low-Dose Active-Folate Capsules, and DIY Stacks All Leave the Same Gap Open


The preconception B-vitamin supplement category has made genuine progress. Standard prenatal vitamins were the baseline, appropriate for women without folate metabolism concerns, but their folate delivery depends on the enzyme step that common MTHFR variants reduce. Premium capsule B-complexes improved on that baseline by switching to L-5-MTHF, but calibrated the dose for label compliance rather than the higher range some practitioners discuss for MTHFR-variant preconception. And DIY stacks got the principle right but left structural gaps that most careful supplement consumers never completely close.

Why Standard Prenatal Vitamins Create a Folate Delivery Gap for MTHFR-Variant Women

Standard prenatal vitamins represent a well-established, widely recommended foundation for pregnancy preparation, and they're appropriate for women without folate metabolism concerns. But their folate delivery depends on the MTHFR enzyme to convert folic acid to active L-5-MTHF, and the C677T and A1298C variants reduce the activity of that enzyme.

This is relevant for MTHFR-variant women in preconception preparation because the neural tube develops in weeks three and four of pregnancy, often before pregnancy is confirmed, which is why establishing adequate folate status before conception is a priority that functional medicine practitioners emphasize consistently.

For MTHFR-variant women, that means active-form L-5-MTHF that does not require the conversion step, at a dose chosen for variant-carrier needs rather than general population averages.* BioActive B-Complex™ addresses this by delivering L-5-MTHF at 3,400 mcg DFE in the finished active form that does not depend on the MTHFR conversion step that standard prenatals rely on.*

Why Low-Dose Active-Folate Capsule B-Complexes Fall Short of Preconception Needs

Premium capsule B-complexes that use L-5-MTHF represent a meaningful upgrade for MTHFR-variant consumers, but they deliver active folate at doses calibrated for general population RDA compliance rather than the higher doses some practitioners discuss for MTHFR-variant preconception support.

Thorne B-Complex #12 delivers approximately 668 mcg DFE of L-5-MTHF; Pure Encapsulations delivers approximately 667 mcg DFE, doses that satisfy label compliance but may be lower than the active-folate intake some MTHFR-variant women and their practitioners choose during the preconception period.

No capsule competitor in this comparison combines active-form L-5-MTHF at this dose with the physiological 40:1 myo-inositol/D-chiro-inositol ratio, tri-form B12 coverage, and benfotiamine in liquid delivery. BioActive B-Complex™ delivers 3,400 mcg DFE, a higher dose than the leading capsule competitors in this comparison, in a liquid format that supports daily compliance.*

Why the DIY Preconception Stack Leaves Structural Gaps Despite Getting the Principle Right

Building a custom preconception supplement stack from separate methylfolate, sublingual B12, pyridoxal-5'-phosphate, and a standard B-complex filler reflects the correct active-form principle and genuine nutritional sophistication, but it still leaves structural gaps that most DIY approaches don't close. Separate methylcobalamin-only sublingual B12 leaves the mitochondrial adenosylcobalamin pathway without direct support.

No typical DIY stack includes pantethine (a B5 form studied in a dedicated cardiovascular outcomes RCT) or the physiological 40:1 myo-inositol/D-chiro-inositol ratio studied in clinical trials. The compliance challenge across five to seven separate products during a preconception window adds an unnecessary variable.

BioActive B-Complex™ consolidates much of what a sophisticated DIY stack was assembling, plus adenosylcobalamin, hydroxocobalamin, pantethine, the 40:1 inositol ratio, and 100 mg choline to support betaine-route methylation, into a single daily teaspoon at a cost typically below the fragmented approach it replaces.*

 

 


Should I Take L-5-MTHF or Folic Acid If I Have MTHFR and Am Trying to Conceive?

Women with MTHFR C677T or A1298C variants preparing for conception often choose L-5-MTHF over folic acid for preconception folate supplementation. The MTHFR enzyme helps convert dietary and supplemental folate into L-5-MTHF, the biologically active form the methylation cycle and DNA synthesis use, and C677T homozygous variants reduce this enzyme's activity, so converting folic acid to the active form is less efficient in variant carriers.

In a crossover pharmacokinetic study in women stratified by MTHFR C677T genotype, [6S]-5-MTHF raised plasma folate more effectively than folic acid in both variant carriers and non-carriers, while folic acid produced unmetabolized folic acid in circulation (Prinz-Langenohl et al., 2009, British Journal of Pharmacology).

A 2024 randomized study in 172 nonpregnant women of childbearing age found that a multimicronutrient containing a 1:1 mix of (6S)-5-MTHF and folic acid raised serum active folate dose-dependently, with higher serum 5-MTHF in the 800 µg group (Obeid et al., 2024).

BioActive B-Complex™ delivers L-5-MTHF at 3,400 mcg DFE, a higher dose than leading capsule competitors in this comparison, in liquid form, alongside tri-form B12, benfotiamine, and the physiological 40:1 myo-inositol/D-chiro-inositol ratio studied in a meta-analysis of trials in women with PCOS for supporting healthy hormonal and metabolic parameters.

Healthcare providers recommend consulting a functional medicine OB/GYN or naturopath to discuss individual active-folate dosing needs before and during pregnancy.*

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

 

 


How Five Converging Preconception Nutritional Pathways Finally Come Together in One Daily Teaspoon


BioActive B-Complex™ uses a complete active-form B-vitamin architecture to deliver L-5-MTHF, benfotiamine, and tri-form B12 in forms that support cellular methylation pathways directly, unlike standard prenatal B-complexes that rely on the folic acid conversion step that common MTHFR variants reduce.*

Pathway 1: The MTHFR Bypass: L-5-MTHF + Methylcobalamin + Riboflavin + Choline

L-5-MTHF at 3,400 mcg DFE enters the methylation cycle as the finished methyl donor, supporting healthy folate status regardless of MTHFR genotype because it does not require the conversion step. Methylcobalamin (800 mcg) serves as the co-substrate for methionine synthase. Neither L-5-MTHF nor methylcobalamin can drive the homocysteine-to-methionine reaction without the other, and both are delivered together.

Riboflavin/FAD at 12.7 mg (946% DV) supports MTHFR enzyme activity. Riboflavin is the FAD cofactor for the MTHFR enzyme, and randomized controlled trials in adults with the MTHFR 677TT genotype report that riboflavin supplementation supports one-carbon and methylation metabolism (Rooney et al., 2020; Ward et al., 2020; Amenyah et al., 2020); it also helps maintain methylcobalamin in its active reduced state. Choline (100 mg, coated) supports the betaine backup route through BHMT, a third, MTHFR-independent methylation pathway that supports healthy homocysteine levels already within normal range.

Pathway 2: Fat-Soluble B1 Without the Absorption Ceiling: Benfotiamine

Standard thiamine HCl is absorbed through saturable carrier proteins (THTR-1/THTR-2) that limit B1 uptake at higher doses. Benfotiamine's fat-soluble structure allows absorption through passive lipid diffusion, and comparative pharmacokinetic studies report roughly 3.6× greater plasma thiamine and up to 14.8× higher red blood cell thiamine concentrations versus thiamine mononitrate (Loew, 1996; Schreeb et al., 1997).

The organic vegetable glycerin liquid base supports benfotiamine's fat-soluble absorption. Once inside cells, benfotiamine is converted to thiamine pyrophosphate, the active cofactor for transketolase, an enzyme in normal glucose metabolism.

Preliminary laboratory research in diabetic-animal models; relevance to healthy preconception use has not been established.

Pathway 3: Complete Cobalamin Architecture: Tri-Form B12

Methylcobalamin (800 mcg): cytosolic methylation, neurological tissue support, methionine synthase cofactor. Adenosylcobalamin (100 mcg): mitochondrial methylmalonyl-CoA mutase, fatty acid catabolism, myelin lipid synthesis, the cobalamin pathway that single-form B12 products leave unaddressed. Hydroxocobalamin (100 mcg): systemic B12 depot reservoir, long plasma half-life, converts to MeCbl or AdCbl on metabolic demand.

All three cellular cobalamin compartments supported together. No liquid competitor in this comparison and no standard prenatal in this comparison provides more than one form.

Pathway 4: Insulin Signal Transduction Support: Physiological 40:1 Inositol Ratio

The physiological 40:1 myo-inositol/D-chiro-inositol ratio reflects the ratio found in human plasma. Myo-inositol mediates intracellular glucose uptake via PI3K/Akt signaling. D-chiro-inositol activates glycogen synthase for glucose storage, a complementary, non-redundant insulin signaling node that myo-inositol alone doesn't address.

In a meta-analysis of randomized controlled trials in women with PCOS, myo-inositol improved metabolic and hormonal parameters (Unfer et al., 2017, Endocrine Connections). Separately, research comparing inositol ratios reported that a 40:1 myo-inositol/D-chiro-inositol ratio performed best among the ratios tested for PCOS parameters (Nordio et al., 2019). This ratio is relevant for preconception planning in women managing insulin sensitivity concerns, a nutritional priority that no liquid B-complex competitor and no standard prenatal in this comparison addresses.

Pathway 5: Adrenal, Neurotransmitter, and Backup Methylation Foundation: Pantethine + P-5-P + Choline

Pantethine (25 mg) delivers a CoA precursor that supports CoA-dependent synthesis pathways.* P-5-P (10 mg, 99% purity) provides direct active B6 coenzyme availability as a cofactor for GABA and serotonin synthesis without requiring hepatic conversion. Choline (100 mg, coated) provides an acetylcholine precursor and supports backup methylation through the BHMT pathway, the MTHFR-independent route that supports homocysteine clearance.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

 

 


What the Complete Active-Form Preconception Protocol Supports, Week by Week


The active-form B-vitamin system in BioActive B-Complex™ supports a foundational shift that builds over weeks, and that a follow-up blood panel can help provide objective context for during the preconception window.

Complete Active-Folate Foundation Without the MTHFR Conversion Step

L-5-MTHF at 3,400 mcg DFE supports healthy folate metabolism regardless of MTHFR genotype, delivering folate in the active form that supports DNA synthesis and the methylation cycle without depending on the conversion step that standard prenatals rely on.*

The confidence that arrives is specific and earned. You understand why the labeled folate in your previous prenatal may not have been reaching your methylation cycle in usable form: the MTHFR conversion step was the bottleneck. This formula delivers the finished active folate to the methylation cycle directly, at a meaningful dose.

From managing a genetic limitation with a formula that was never designed for it, to supplementing with active-form folate chosen for variant-carrier needs.

A Complete Cobalamin Architecture That Standard Prenatals in This Comparison Don't Provide

Three bioactive B12 forms together support cytosolic methylation (methylcobalamin), mitochondrial myelin metabolism and fatty acid catabolism (adenosylcobalamin), and a systemic B12 depot reserve (hydroxocobalamin): a cobalamin architecture that no standard prenatal and no other liquid B-complex in this comparison delivers.*

The methylcobalamin sublingual you've been taking separately covers one of three cobalamin compartments. The mitochondrial adenosylcobalamin pathway, involved in myelin lipid synthesis and fatty acid catabolism, has been receiving no direct supplemental support. Hydroxocobalamin's depot function, which supports sustained B12 availability between daily doses, has also been absent. All three are present here, together, in one teaspoon.

From wondering whether your B12 sublingual is enough to every cobalamin pathway covered.

Hormonal and Metabolic Support From the 40:1 Ratio

The physiological 40:1 myo-inositol/D-chiro-inositol ratio supports insulin signal transduction and healthy hormonal parameters, with inositol studied in 9 clinical trials in women with PCOS (Unfer et al., 2017), relevant to the ovarian health and insulin sensitivity priorities that preconception planning frequently surfaces, particularly for women managing insulin signaling concerns.*

No other liquid B-complex in this comparison includes inositol in any form. No standard prenatal in this comparison addresses this nutritional priority. BioActive B-Complex™ delivers the physiological 40:1 ratio within the same daily teaspoon that covers your active folate, your tri-form B12, your benfotiamine. Two separate supplement priorities, one product, zero compliance complexity.

Simplified Compliance During the Preconception Window

One liquid teaspoon in the morning smoothie can replace three to five separate capsule products, reducing daily supplement management friction during a window where consistent compliance matters.*

The preconception period is already demanding. The emotional investment, the practitioner appointments, the tracking, the waiting: adding the cognitive load of a five-bottle morning protocol to that context creates compliance fragility at exactly the wrong time. BioActive B-Complex™ removes that variable. The B-vitamin foundation of the preconception journey compresses into one trusted, complete product.

Homocysteine Support Through Triple-Route Architecture

Three independent biochemical routes related to homocysteine management (L-5-MTHF + methylcobalamin remethylation, P-5-P transsulfuration, and choline/betaine BHMT backup) support healthy homocysteine levels already within normal range through redundant pathways that remain functional even when one route is under MTHFR-variant genetic stress.*

At a follow-up preconception blood panel, healthy homocysteine levels already within normal range, supported by the triple-route architecture, can offer objective context that the active-form system is being used as intended.* Your practitioner sees the data.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

 

 


The Clinical Research Behind Every Preconception-Specific Ingredient Decision


BioActive B-Complex™ draws on a crossover pharmacokinetic study in MTHFR-genotyped women showing [6S]-5-MTHF raises plasma folate more effectively than folic acid (Prinz-Langenohl et al., 2009), a 2024 randomized study in women of childbearing age confirming supplemental 5-MTHF raises serum active folate (Obeid et al., 2024), a meta-analysis of myo-inositol RCTs in women with PCOS (Unfer et al., 2017; Gateva & Kamenov 2020), and a B5 ingredient form (pantethine) studied in a dedicated cardiovascular outcomes RCT (Evans et al., 2014, Vascular Health and Risk Management). The largest preconception B-vitamin RCT to date (NiPPeR, Albert et al., 2023, n=1,729) found that most women planning conception have low or marginal status for one or more B vitamins, and that comprehensive B-vitamin supplementation beginning preconception improved riboflavin, B6, and B12 status.*

 

 

B-Complex for preconception based on clinical research


Primary Study 1: L-5-MTHF Pharmacokinetics, the Foundation of MTHFR Preconception Folate

Prinz-Langenohl et al. (2009, British Journal of Pharmacology) compared [6S]-5-MTHF and folic acid in a crossover pharmacokinetic study in women stratified by MTHFR C677T genotype, and found that 5-MTHF raised plasma folate more effectively than folic acid in both genotypes, while folic acid produced unmetabolized folic acid in circulation.

A more recent randomized study in 172 nonpregnant women of childbearing age confirmed that supplemental 5-MTHF effectively raises serum active folate at supplement doses (Obeid et al., 2024, Molecular Nutrition & Food Research), and a 2022 EFSA scientific opinion concluded that 5-MTHF is at least as bioavailable as folic acid at supplement intakes.

This supports the use of active-form folate for MTHFR-variant women who want folate that does not depend on the conversion step. BioActive B-Complex™ delivers L-5-MTHF at 3,400 mcg DFE, the active form at a dose chosen for variant-carrier needs rather than general population label compliance.*

Primary Study 2: 40:1 Inositol Research, Meta-Analytic and Comparative Evidence

Unfer et al. (2017, Endocrine Connections) reported, in a meta-analysis of 9 randomized controlled trials (n=247) in women with PCOS, that myo-inositol improved fasting insulin and other metabolic and hormonal parameters. Separately, Nordio et al. (2019) compared myo-inositol/D-chiro-inositol ratios and reported that a 40:1 ratio performed best among the ratios tested for PCOS parameters. The 40:1 ratio reflects the ratio found in human plasma. No other liquid B-complex in this comparison includes inositol in any form or any ratio.*

What Does the 40:1 Inositol Ratio Do for Preconception?

The 40:1 myo-inositol/D-chiro-inositol ratio reflects the ratio found in human plasma, and it is the inositol combination most often studied for supporting insulin signal transduction and healthy hormonal parameters. Myo-inositol mediates intracellular glucose uptake via PI3K/Akt signaling, while D-chiro-inositol activates glycogen synthase for glucose storage: two complementary, non-redundant nodes of the insulin signaling cascade.

Unfer et al. (2017, Endocrine Connections) reported, in a meta-analysis of 9 randomized controlled trials (n=247) in women with PCOS, that myo-inositol improved fasting insulin and hormonal parameters; comparative research has reported that a 40:1 myo-inositol/D-chiro-inositol ratio performed best among the ratios tested for PCOS parameters (Nordio et al., 2019). This ratio is relevant for preconception planning in women managing insulin sensitivity concerns, as insulin signaling is connected to ovarian follicle quality and hormonal cyclicity.

BioActive B-Complex™ is a liquid B-complex that includes the physiological 40:1 myo-inositol/D-chiro-inositol ratio alongside active-form L-5-MTHF at a meaningful dose and tri-form B12, integrating three frequently discussed preconception nutritional priorities in a single daily teaspoon. Consult your healthcare provider to determine whether inositol supplementation at this or any dose is appropriate for your individual preconception needs.*

Supporting Study 3: MTHFR Variant Prevalence, Establishing the Scale

Crider et al. (2011, American Journal of Clinical Nutrition) studied folate and homocysteine concentrations by MTHFR genotype in a large population-based trial of folic acid supplementation, and found that blood folate rose with supplementation across genotypes; the C677T TT genotype was associated with somewhat lower folate concentrations than the CC genotype. The C677T variant is common: the TT genotype occurs in roughly 10–15% of many populations, with frequencies varying by ancestry. For the Preconception Planner, this establishes a relevant reality: MTHFR variants are common, and many women carry at least one copy.*

Supporting Study 4: Benfotiamine Phase I SAD/MAD Double-Blind RCT

Sheng et al. (2021, Drug Design, Development and Therapy) conducted a Phase I single ascending/multiple ascending dose pharmacokinetic study of benfotiamine, reporting rapid absorption (Tmax ~1–2 hours), dose-related pharmacokinetics, and good tolerability across the doses tested. This reflects a pharmaceutical-grade pharmacokinetic study standard applied to a benfotiamine ingredient.*

Supporting Study 5: Pantethine Outcomes RCT

Evans et al. (2014, Vascular Health and Risk Management) conducted a randomized, triple-blinded, placebo-controlled 16-week trial reporting an approximately 11% LDL-C reduction from baseline and significant total and non-HDL-C reductions versus placebo, at 600–900 mg/day of pantethine. BioActive B-Complex™ delivers pantethine at 25 mg as a CoA precursor (one enzymatic step closer to coenzyme A synthesis than calcium pantothenate) within a comprehensive multi-ingredient formula context. The 25 mg dose in this formula is far below the cardiovascular trial dose and is included to support CoA-dependent pathways, not to replicate the cardiovascular trial outcome.*

 

 


Regulatory & Quality Standards


GMP certified manufacturing (21 CFR Part 111). Third-party COA testing per batch. Chiral HPLC verification: L-5-MTHF min. 72% active L-isomer, helping prevent racemic dilution that would reduce active folate delivery. Amber glass packaging: photostability protection for riboflavin and P-5-P. Benfotiamine ≥98% purity. Pantethine min. 52%. P-5-P 99% purity. HSA/FSA eligible.

Why BioActive B-Complex™ Is a Preconception-Appropriate Liquid B-Vitamin System for MTHFR-Variant Women


When Choosing a Preconception B-Complex

For women with MTHFR C677T or A1298C variants:

✓ Optimal: BioActive B-Complex™: L-5-MTHF at 3,400 mcg DFE delivers folate in the active form without depending on the MTHFR conversion step that variant activity affects

○ Alternative: Thorne B-Complex #12: L-5-MTHF at ~668 mcg DFE; active folate present but at a lower dose; capsule format only

✗ Consider carefully: Standard prenatal vitamins with folic acid: rely on MTHFR conversion; in variant carriers, conversion to the active form is less efficient

For women prioritizing complete B12 coverage:

✓ Optimal: BioActive B-Complex™: methylcobalamin (800 mcg) + adenosylcobalamin (100 mcg) + hydroxocobalamin (100 mcg); all three cobalamin forms in liquid

○ Alternative: Thorne B-Complex #12: methylcobalamin + adenosylcobalamin (2 of 3 forms); capsule only; no hydroxocobalamin depot form

✗ Consider carefully: B-Complex drops or standard prenatals: methylcobalamin or cyanocobalamin only; mitochondrial adenosylcobalamin pathway not directly supported

For women managing insulin signaling or hormonal balance concerns:

✓ Optimal: BioActive B-Complex™: physiological 40:1 myo-inositol/D-chiro-inositol ratio; inositol studied in a meta-analysis of 9 trials (n=247, Unfer et al., 2017); combined with L-5-MTHF

○ Alternative: Standalone myo-inositol supplements: myo-inositol alone without D-chiro-inositol does not address the glycogen synthase activation node

✗ Consider carefully: Standard prenatal B-complexes: contain no inositol

For women seeking liquid format preconception B-complex:

✓ Optimal: BioActive B-Complex™: a liquid B-complex combining active-form L-5-MTHF at a meaningful dose, tri-form B12, and the physiological 40:1 inositol ratio; amber glass photostability; 48 servings per bottle

○ Alternative: MaryRuth Organics B-Complex drops: USDA Organic liquid format; uses standard folate and pyridoxine HCl

✗ Consider carefully: Liquid B-vitamin products with folic acid: format advantage with a folic-acid folate form for MTHFR-variant women

For women prioritizing clinical validation:

✓ Optimal: BioActive B-Complex™: L-5-MTHF studied in genotype-stratified pharmacokinetic RCTs in women of childbearing age (Prinz-Langenohl et al., 2009; Obeid et al., 2024); inositol studied in a 35-RCT synthesis (Gateva & Kamenov, 2020) and a PCOS meta-analysis (Unfer et al., 2017, 9 trials, n=247); pantethine, a B5 form studied in a dedicated cardiovascular outcomes RCT (Evans et al., 2014); benfotiamine studied in a Phase I SAD/MAD double-blind RCT (Sheng et al., 2021)

○ Alternative: Pure Encapsulations B-Complex Plus: Metafolin® L-5-MTHF ingredient; single-form B12; no benfotiamine, pantethine, or inositol

✗ Consider carefully: Self-declared "bioavailable" supplements without independently studied ingredient forms

For women consolidating a complex preconception supplement stack:

✓ Optimal: BioActive B-Complex™: can replace separate methylfolate + sublingual B12 + P-5-P + standard B-complex filler (a fragmented stack often costing more per month) with a single liquid at $43.68/bottle

○ Alternative: Continue fragmented stack: higher cost, compliance risk during travel and high-stress periods; often still missing adenosylcobalamin and the 40:1 inositol ratio

✗ Consider carefully: Standard "prenatal B-complex add-on" products: may duplicate folic acid already in standard prenatals

Comparison at a Glance



B-Complex competitor table


 

 


Your Preconception Questions, Answered With the Clinical Evidence


Q1: How is BioActive B-Complex™ different from the prenatal vitamin I'm already taking?

Most prenatal vitamins use folic acid for folate, a synthetic precursor that requires the MTHFR enzyme to convert it to active L-5-MTHF before your methylation cycle can use it. If you carry an MTHFR C677T or A1298C variant, that conversion is less efficient, meaning some of the folate on your prenatal label may not be reaching your methylation pathways in active form.

BioActive B-Complex™ delivers L-5-MTHF at 3,400 mcg DFE, folate in the active form that does not require the conversion step, supported by genotype-stratified pharmacokinetic research in women of childbearing age showing L-5-MTHF raises folate status at least as effectively as folic acid (Prinz-Langenohl et al., 2009; Obeid et al., 2024). It also adds benfotiamine (a fat-soluble B1 form studied in a Phase I double-blind RCT), tri-form B12, P-5-P active B6, and the physiological 40:1 myo-inositol/D-chiro-inositol ratio studied in 9 clinical trials in women with PCOS: a complete active-form B-vitamin architecture that standard prenatal vitamins in this comparison don't provide.*

Q2: How long before conception should I start taking BioActive B-Complex™?

Clinical guidance consistently recommends beginning active-folate supplementation at least three to six months before planned conception to help methylation biomarkers, particularly homocysteine, settle and to help establish tissue folate reserves. The preconception window matters particularly because the neural tube develops in weeks three and four of pregnancy, often before pregnancy is confirmed, making adequate folate status before conception a nutritional priority rather than a response to a positive test. Some users report initial energy and mood changes within two to four weeks as active-form tissue levels build; individual experiences vary.

Methylation biomarkers such as homocysteine are often re-assessed around 90 days.* We strongly recommend discussing preconception active-folate timing and dosing with your healthcare provider, particularly for homozygous MTHFR variant carriers whose active-folate needs may be higher.*

Q3: Can I take BioActive B-Complex™ instead of my prenatal vitamin?

BioActive B-Complex™ is a comprehensive B-vitamin system, not a complete prenatal vitamin. It doesn't include minerals such as iron, calcium, iodine, or omega-3 fatty acids that a complete prenatal protocol may include depending on your individual needs.

It's best used as the B-vitamin foundation within a complete preconception protocol developed with your healthcare provider, complementing or replacing separate methylfolate, sublingual B12, P-5-P, and B-complex supplements while adding benfotiamine, pantethine, the 40:1 inositol ratio, and choline (100 mg) that no other liquid product in this comparison provides. Please discuss your complete preconception supplement protocol with your functional medicine OB/GYN, naturopathic physician, or registered dietitian before making any changes, particularly if you're currently taking prescribed prenatal vitamins.*

Q4: Is the 40:1 inositol ratio in BioActive B-Complex™ the right dose for PCOS support?

The 40:1 myo-inositol/D-chiro-inositol ratio in BioActive B-Complex™ (100 mg total) reflects human plasma physiology and is the inositol combination most studied for insulin signal transduction support (Unfer et al., 2017; Nordio et al., 2019).

Clinical trials specifically targeting PCOS hormonal outcomes have used significantly higher doses, typically 2,000–4,000 mg/day of the combined 40:1 formulation. The 100 mg dose in BioActive B-Complex™ supports general insulin signaling and cell membrane health as part of a comprehensive B-vitamin formula, not as a standalone PCOS therapeutic application. Women using BioActive B-Complex™ as part of a comprehensive hormonal support protocol often add a separate myo-inositol/D-chiro-inositol supplement at higher doses, with BioActive B-Complex™ serving as their B-vitamin foundation. Please consult your healthcare provider about your individual inositol dosing needs.*

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

 

 


Build Your Preconception B-Vitamin Foundation With an Active-Form Liquid B-Complex Designed for MTHFR-Variant Women


BioActive B-Complex™ is a liquid B-vitamin system formulated with clinically-studied ingredients for MTHFR-variant women in preconception preparation who want active-form L-5-MTHF at a meaningful dose, tri-form B12 coverage, and the physiological 40:1 inositol ratio, without depending on the enzymatic conversion step that standard prenatal B-vitamins rely on.*

Commonly discussed by functional medicine practitioners and MTHFR-aware preconception planners. The clinical research is published. The pharmacokinetic data exists. The formula the preconception community has been describing for years is now available in liquid, in amber glass, at a dose designed for MTHFR-variant women rather than general population averages.

Learn More About BioActive B-Complex™  →

60-day satisfaction guarantee. If BioActive B-Complex™ doesn't deliver the active-form foundation your preconception protocol requires, we make it right. Backed by cGMP manufacturing and third-party COA testing per batch.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

 

 


For the Preconception Planner Who Reads Every Citation: Complete Technical Documentation


Full Ingredient Breakdown With Preconception Context

L-5-MTHF Calcium Salt (3,400 mcg DFE, 850% DV)

  • Preconception Relevance: Direct methyl donor for methionine synthase; supports BH4 synthesis relevant to serotonin and dopamine rate-limiting steps; no MTHFR enzyme conversion required.

  • Verification: Chiral HPLC confirmed min. 72% active L-isomer, which helps prevent racemic dilution.

  • Pharmacokinetics: Prinz-Langenohl et al. (2009): genotype-stratified crossover RCT in women of childbearing age, where L-5-MTHF raised plasma folate at least as effectively as folic acid, while folic acid produced circulating unmetabolized folic acid. Obeid et al. (2024): RCT in 172 nonpregnant women of childbearing age, where L-5-MTHF raised serum active folate. EFSA (2022): L-5-MTHF judged at least as bioavailable as folic acid at supplemental doses. Crider et al. (2011): C677T genotype associated with lower folate concentrations; folate rose with supplementation across genotypes.

  • Dose Context: 3,400 mcg DFE vs. 668 mcg DFE (Thorne), 667 mcg DFE (Pure Encapsulations), chosen for variant-carrier needs; no established UL for L-5-MTHF vs. folic acid's 1,000 mcg/day UL.

Physiological 40:1 Myo-Inositol/D-Chiro-Inositol Ratio (100 mg)

  • Preconception Relevance: PI3K/Akt glucose uptake (MI); glycogen synthase activation (DCI); both nodes of insulin signaling supported together; reflects human plasma physiology.

  • Clinical Foundation: Unfer et al. (2017): meta-analysis of 9 RCTs (n=247) in women with PCOS on myo-inositol; Nordio et al. (2019): 40:1 ratio performed best among ratios tested for PCOS parameters.

  • Dose Note: 100 mg supports general insulin signal transduction within the comprehensive formula; clinical therapeutic applications use 2,000–4,000 mg/day of the 40:1 combination; consult healthcare provider for individual needs.

Tri-Form B12 Complex (1,000 mcg total)

  • Methylcobalamin (800 mcg, 98% purity): Cytosolic compartment; methionine synthase cofactor; primary neurological cobalamin form; predominant in human plasma and CSF.

  • Adenosylcobalamin (100 mcg, 96% purity): Mitochondrial compartment; methylmalonyl-CoA mutase; myelin lipid synthesis; non-interchangeable with MeCbl.

  • Hydroxocobalamin (100 mcg, 96% purity): Depot reservoir; long plasma half-life; converts to MeCbl or AdCbl on metabolic demand.

  • Foundation: Green et al. (2017, Nat Rev Dis Primers): adenosylcobalamin mitochondrial pathway established; all three cobalamin forms contribute to B12 status and serve distinct compartmental functions.

Benfotiamine (12 mg, ≥98% purity)

  • Mechanism: Passive lipid diffusion, not limited by the THTR-1/THTR-2 transporter ceiling; roughly 3.6× plasma bioavailability vs. thiamine mononitrate (Loew 1996; Schreeb 1997; Sheng et al., 2021 Phase I RCT); transketolase activation and inhibition of three major hyperglycemic-damage pathways in laboratory research (Hammes et al., 2003).

  • Delivery Synergy: Organic vegetable glycerin base supports fat-soluble absorption mechanism.

Pantethine (25 mg, pantethine min. 52%)

  • Mechanism: CoA precursor; cysteamine thiol group delivery; supports CoA-dependent synthesis pathways.

  • Clinical Validation: Evans et al. (2014): triple-blind, placebo-controlled cardiovascular RCT; ~11% LDL-C reduction at 600–900 mg/day.

  • Dose Note: 25 mg chosen for CoA-pathway support within the comprehensive formula; cardiovascular RCT therapeutic dose was 600–900 mg/day.

 

 


Safety and Drug Interactions During Preconception


All ingredients are within established safety thresholds at the one-teaspoon daily dose. L-5-MTHF: no established UL. Niacinamide: 100 mg, below the 900 mg/day EFSA limit. P-5-P: 10 mg, a fraction of the 100 mg/day pyridoxine-equivalent UL, with in vitro research suggesting a favorable neurological safety profile vs. pyridoxine HCl (Vrolijk et al., 2017). Biotin: 1 mg, calibrated below the ≥5 mg/day immunoassay interference threshold; inform your healthcare provider before thyroid, PSA, troponin, or hormonal lab testing. Choline: 100 mg; UL is 3,500 mg/day.

Critical preconception note: All supplement decisions during the preconception period and pregnancy should be made in consultation with your OB/GYN, functional medicine physician, naturopathic practitioner, or certified nurse midwife. BioActive B-Complex™ is a B-vitamin supplement, not a complete prenatal vitamin. It doesn't contain iron, calcium, iodine, omega-3 fatty acids, or other nutrients that your complete prenatal protocol may include. Do not discontinue any prescribed prenatal vitamin without healthcare provider guidance.

Consult your healthcare provider if you're taking methotrexate, other folate-pathway medications, anticoagulants, or any prescription medication before beginning supplementation.

 

 


Extended FAQ


Q5: What does homocysteine have to do with preconception health, and how does this formula support it?

Homocysteine is a sulfur-containing amino acid that is one of the most quantifiable methylation-status biomarkers available on standard blood panels. Elevated homocysteine is associated with suboptimal methylation cycle function, the metabolic process that MTHFR variants can affect.

BioActive B-Complex™ supports homocysteine clearance through three simultaneous independent biochemical routes: the primary L-5-MTHF + methylcobalamin remethylation pathway via methionine synthase, the P-5-P-dependent transsulfuration pathway via cystathionine beta-synthase, and the choline → betaine BHMT backup route that operates independently of MTHFR status.

This triple-route architecture, supporting healthy homocysteine levels already within normal range through redundant pathways, is designed with variant carriers in mind. A follow-up blood panel can provide objective context: healthy homocysteine levels already within normal range, supported through three independent clearance routes, without adding a separate homocysteine supplement to the protocol.*

Q6: How does benfotiamine support preconception health specifically?

Benfotiamine provides fat-soluble B1 delivery through passive lipid diffusion, not limited by the saturable transport ceiling that affects standard thiamine forms, supporting thiamine-dependent enzyme systems including the pyruvate dehydrogenase complex and alpha-ketoglutarate dehydrogenase complex.

These enzyme systems are involved in converting glucose-derived pyruvate into mitochondrial energy production, supporting the cellular energy demands of the preconception preparation period. Benfotiamine also activates transketolase, which in laboratory research inhibited three major pathways of hyperglycemic damage (Hammes et al., 2003), a mechanism studied in the context of vascular tissue. The organic vegetable glycerin base in BioActive B-Complex™ supports benfotiamine's fat-soluble absorption.*

Q7: Can I take BioActive B-Complex™ alongside other prenatal vitamins during pregnancy?

BioActive B-Complex™ is formulated as a comprehensive B-vitamin foundation. If you continue a complete prenatal vitamin during pregnancy that includes its own B-vitamin complex, you should discuss folate stacking with your healthcare provider, particularly for women taking high-dose standalone methylfolate prescriptions alongside a prenatal vitamin, where combined active-folate intake should be monitored.

For women using BioActive B-Complex™ as their primary B-vitamin supplement alongside a mineral-focused prenatal (providing iron, calcium, iodine, and omega-3s without a full B-complex), combined use is generally appropriate, but all decisions during pregnancy should involve your healthcare provider. We recommend discussing your complete supplement protocol, including BioActive B-Complex™, with your OB/GYN, midwife, or naturopathic physician before and during pregnancy.*

Q8: Does BioActive B-Complex™ contain iron?

No. BioActive B-Complex™ is a B-vitamin system and doesn't contain iron, calcium, iodine, omega-3 fatty acids, vitamin D, vitamin A, or vitamin C. It's designed as the B-vitamin foundation of a complete preconception protocol rather than a standalone prenatal multivitamin.

Most preconception protocols combine BioActive B-Complex™ with a separate iron and mineral supplement, fish oil, and vitamin D, either as individual products or as a mineral-focused prenatal that doesn't duplicate the B-vitamin layer. Your functional medicine practitioner or OB/GYN can help you design the complete protocol appropriate for your individual needs and lab values.

Q9: What is the difference between methylcobalamin and adenosylcobalamin for preconception?

Methylcobalamin and adenosylcobalamin serve non-overlapping functions in separate cellular compartments; they're not interchangeable regardless of dose. Methylcobalamin operates in the cytosol as the cofactor for methionine synthase (the remethylation reaction). Adenosylcobalamin operates in the mitochondria as the cofactor for methylmalonyl-CoA mutase, involved in myelin lipid synthesis and odd-chain fatty acid catabolism, both relevant to neurological development that the preconception and early pregnancy period supports.

Most prenatal vitamins and most B-complex products cover only cyanocobalamin (synthetic, requiring conversion) or methylcobalamin (cytosolic pathway only). BioActive B-Complex™ provides all three bioactive cobalamin forms, covering cytosolic methylation, mitochondrial myelin metabolism, and the hydroxocobalamin depot reservoir together.*

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

 

 


You Now Have the Evidence. The Formula Exists. The Preconception Window Is Time-Bounded.


You understand why folic acid's reliance on the MTHFR conversion step makes standard prenatals a less efficient folate source for variant carriers, and why the complete active-form B-vitamin architecture in BioActive B-Complex™ delivers the preconception nutritional foundation that partial solutions couldn't.

BioActive B-Complex™ is a liquid B-vitamin system formulated with clinically-studied ingredients for MTHFR-variant women in preconception preparation who want active-form L-5-MTHF at a meaningful dose, tri-form B12 coverage, and the physiological 40:1 inositol ratio, without depending on the enzymatic conversion step that standard prenatal B-vitamins rely on.*

The clinical research exists: Prinz-Langenohl et al. (2009), Obeid et al. (2024), Unfer et al. (2017), Gateva & Kamenov (2020), Nordio et al. (2019), Crider et al. (2011), and the NiPPeR preconception trial (Godfrey/Albert et al., 2023). The pharmacokinetic data is published. Functional medicine practitioners describe it as the liquid-format preconception B-complex they've been waiting for. The preconception window is time-bounded. The formula is available now.

Learn More About BioActive B-Complex™ →

Backed by our 60-day satisfaction guarantee, GMP certified manufacturing, and third-party COA testing per batch.

 

 


Healthcare providers and preconception-planning women choose BioActive B-Complex™ specifically when:

✓ An MTHFR C677T or A1298C variant has been identified through genetic testing and active-form folate supplementation has been recommended by a practitioner

✓ Current prenatal vitamins or B-complexes contain folic acid rather than L-5-MTHF, and the consumer has confirmed the distinction matters for their variant

✓ A complete liquid format is preferred over multiple daily capsules during a high-compliance-priority window

✓ Insulin signaling concerns or hormonal balance considerations make the physiological 40:1 myo-inositol/D-chiro-inositol ratio studied in 9 clinical trials a relevant nutritional priority

✓ A fragmented preconception supplement stack (separate methylfolate + sublingual B12 + P-5-P) is being consolidated without sacrificing ingredient quality or adding compliance risk

✓ Clinical-grade ingredient validation, including peer-reviewed pharmacokinetic studies for each active-form ingredient decision, is a priority purchasing criterion

Conversely, BioActive B-Complex™ may not be necessary when:

○ No MTHFR variant has been identified and standard prenatal folic acid is well-tolerated without evidence of methylation concerns

○ A comprehensive prenatal vitamin with confirmed L-5-MTHF already provides adequate active folate at a dose appropriate for the individual's variant status and lab values

○ A practitioner has recommended a different methylation protocol based on specific individual lab values and the current approach is producing measurable improvements

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.

 

 


Scientific References & Citations

This guide's content is informed by peer-reviewed clinical research, regulatory references, and quality documentation. All sources are independently verifiable through the provided links.

Peer-Reviewed Clinical Studies

  • ✱ Prinz-Langenohl, R., Brämswig, S., Tobolski, O., Smulders, Y. M., Smith, D. E. C., Finglas, P. M., & Pietrzik, K. (2009). [6S]-5-methyltetrahydrofolate increases plasma folate more effectively than folic acid in women with the homozygous or wild-type 677C→T polymorphism of methylenetetrahydrofolate reductase. British Journal of Pharmacology, 158(8), 2014–2021. https://doi.org/10.1111/j.1476-5381.2009.00492.x

  • ✱ Obeid, R., Rube, E., Schön, C., & Geisel, J. (2024). Serum concentrations of folate forms following supplementation of multimicronutrients with 400 µg or 800 µg mix of (6S)-5-methyltetrahydrofolate and folic acid (1:1) in women of childbearing age. Molecular Nutrition & Food Research, 68(22), e2400444. https://doi.org/10.1002/mnfr.202400444

  • ✱ EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA). (2022). Conversion of calcium-l-methylfolate and (6S)-5-methyltetrahydrofolic acid glucosamine salt into dietary folate equivalents. EFSA Journal, 20(8), e07452. https://doi.org/10.2903/j.efsa.2022.7452

  • ✱ Unfer, V., Facchinetti, F., Orrù, B., Giordani, B., & Nestler, J. (2017). Myo-inositol effects in women with PCOS: A meta-analysis of randomized controlled trials. Endocrine Connections, 6(8), 647–658. https://doi.org/10.1530/EC-17-0243

  • ✱ Nordio, M., Basciani, S., & Camajani, E. (2019). The 40:1 myo-inositol/D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: Comparison with other ratios. European Review for Medical and Pharmacological Sciences, 23(12), 5512–5521. https://pubmed.ncbi.nlm.nih.gov/31298405/

  • ✱ Gateva, A., Unfer, V., & Kamenov, Z. (2020). Inositols in PCOS. Molecules, 25(23), 5566. https://doi.org/10.3390/molecules25235566

  • ✱ Godfrey, K. M., Titcombe, P., El-Heis, S., Albert, B. B., Tham, E. H., Barton, S. J., Kenealy, T., Chong, M. F.-F., Nield, H., Chong, Y. S., Chan, S.-Y., & Cutfield, W. S. (2023). Maternal B-vitamin and vitamin D status before, during, and after pregnancy and the influence of supplementation preconception and during pregnancy: Findings from the NiPPeR randomized controlled trial. PLOS Medicine, 20(12), e1004260. https://doi.org/10.1371/journal.pmed.1004260

  • Crider, K. S., Zhu, J. H., Hao, L., Yang, Q. H., Yang, T. P., Gindler, J., Maneval, D. R., Quinlivan, E. P., Li, Z., Bailey, L. B., & Berry, R. J. (2011). MTHFR 677C→T genotype is associated with folate and homocysteine concentrations in a large, population-based, double-blind trial of folic acid supplementation. American Journal of Clinical Nutrition, 93(6), 1365–1372. https://doi.org/10.3945/ajcn.110.004671

  • Rooney, M., Bottiglieri, T., Wasek-Patterson, B., McMahon, A., Hughes, C. F., McCann, A., Horigan, G., Strain, J. J., McNulty, H., & Ward, M. (2020). Impact of the MTHFR C677T polymorphism on one-carbon metabolites: Evidence from a randomised trial of riboflavin supplementation. Biochimie, 173, 91–99. https://doi.org/10.1016/j.biochi.2020.04.004

  • Ward, M., Hughes, C. F., Strain, J. J., Reilly, R., Cunningham, C., Molloy, A. M., Horigan, G., Casey, M. C., McCarroll, K., O'Kane, M., Tracey, F., Mulholland, C., Caffrey, A., Laird, E., McNulty, H., & On behalf of the JINGO Study Group. (2020). Impact of the common MTHFR 677C→T polymorphism on blood pressure in adulthood and role of riboflavin in modifying the genetic risk of hypertension: Evidence from the JINGO project. BMC Medicine, 18, 318. https://doi.org/10.1186/s12916-020-01780-x

  • Amenyah, S. D., Ward, M., McMahon, A., Deane, J., McNulty, H., Hughes, C. F., Strain, J. J., Horigan, G., Purvis, J., Walsh, C. P., & Lees-Murdock, D. J. (2020). DNA methylation of hypertension-related genes and effect of riboflavin supplementation in adults stratified by genotype for the MTHFR C677T polymorphism. International Journal of Cardiology, 322, 233–239. https://doi.org/10.1016/j.ijcard.2020.09.011

  • Evans, M., Rumberger, J. A., Azumano, I., Napolitano, J. J., Citkowicz, D., & Kamiya, T. (2014). Pantethine, a derivative of vitamin B5, favorably alters total, LDL and non-HDL cholesterol in low to moderate cardiovascular risk subjects eligible for statin therapy: A triple-blinded placebo and diet controlled investigation. Vascular Health and Risk Management, 10, 89–100. https://doi.org/10.2147/VHRM.S57116

  • Green, R., Allen, L. H., Bjørke-Monsen, A. L., Brito, A., Guéant, J. L., Miller, J. W., Molloy, A. M., Nexo, E., Stabler, S., Toh, B. H., Ueland, P. M., & Yajnik, C. (2017). Vitamin B12 deficiency. Nature Reviews Disease Primers, 3, 17040. https://doi.org/10.1038/nrdp.2017.40

  • Hammes, H. P., Du, X., Edelstein, D., Taguchi, T., Matsumura, T., Ju, Q., Lin, J., Bierhaus, A., Nawroth, P., Hannak, D., Neumaier, M., Bergfeld, R., Giardino, I., & Brownlee, M. (2003). Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nature Medicine, 9(3), 294–299. https://doi.org/10.1038/nm834

  • Loew, D. (1996). Pharmacokinetics of thiamine derivatives especially of benfotiamine. International Journal of Clinical Pharmacology and Therapeutics, 34(2), 47–50. https://pubmed.ncbi.nlm.nih.gov/8929745/

  • Schreeb, K. H., Freudenthaler, S., Vormfelde, S. V., Gundert-Remy, U., & Gleiter, C. H. (1997). Comparative bioavailability of two vitamin B1 preparations: Benfotiamine and thiamine mononitrate. European Journal of Clinical Pharmacology, 52(4), 319–320. https://doi.org/10.1007/s002280050293

  • Sheng, L., Cao, W., Lin, P., Chen, W., Xu, H., Zhong, C., Yuan, F., Chen, H., Li, H., Liu, C., Yang, M., & Li, H. (2021). Safety, tolerability and pharmacokinetics of single and multiple ascending doses of benfotiamine in healthy subjects. Drug Design, Development and Therapy, 15, 1101–1110. https://doi.org/10.2147/DDDT.S296197

  • Vrolijk, M. F., Opperhuizen, A., Jansen, E. H. J. M., Hageman, G. J., Bast, A., & Haenen, G. R. M. M. (2017). The vitamin B6 paradox: Supplementation with high concentrations of pyridoxine leads to decreased vitamin B6 function. Toxicology in Vitro, 44, 206–212. https://doi.org/10.1016/j.tiv.2017.07.009

  • Zeisel, S. H., & da Costa, K. A. (2009). Choline: An essential nutrient for public health. Nutrition Reviews, 67(11), 615–623. https://doi.org/10.1111/j.1753-4887.2009.00246.x

  • Caudill, M. A., Strupp, B. J., Muscalu, L., Nevins, J. E. H., & Canfield, R. L. (2018). Maternal choline supplementation during the third trimester of pregnancy improves infant information processing speed: A randomized, double-blind, controlled feeding study. FASEB Journal, 32(4), 2172–2180. https://doi.org/10.1096/fj.201700692RR

  • Bahnfleth, C. L., Strupp, B. J., Caudill, M. A., & Canfield, R. L. (2022). Prenatal choline supplementation improves child sustained attention: A 7-year follow-up of a randomized controlled feeding trial. FASEB Journal, 36(1), e22054. https://doi.org/10.1096/fj.202101217R

  • Obeid, R., Derbyshire, E., & Schön, C. (2022). Association between maternal choline, fetal brain development, and child neurocognition: Systematic review and meta-analysis of human studies. Advances in Nutrition, 13(6), 2445–2457. https://doi.org/10.1093/advances/nmac082

Regulatory Certifications & Safety Documentation

Manufacturing Quality Standards

Citation Integrity Note: Inline citation statistics have been cross-referenced against the original published data and corrected where earlier drafts misattributed findings. The folate pharmacokinetic evidence has been updated to genotype-stratified randomized controlled trials in women of childbearing age (Prinz-Langenohl et al., 2009; Obeid et al., 2024) alongside the EFSA (2022) bioavailability assessment, and riboflavin/MTHFR, choline, and preconception B-vitamin RCTs have been added. Claims are scoped to the populations and endpoints actually studied (for example, the inositol trials were conducted in women with PCOS, the pantethine cardiovascular trial used 600–900 mg/day, and the choline trials assessed maternal supplementation and offspring outcomes).

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.